BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis.
David Oliveira Dos Santos, Amir Mohamed, Adam Mohamed, José Miguel Alvarenga, Tiago Torres
Published: 202610.1007/s40259-025-00762-w
Abstract
Atopic dermatitis is a chronic inflammatory skin disease affecting approximately 15-20% of children and 2-10% of adults worldwide. Epidermal barrier dysfunction and immune dysregulation are central to its pathogenesis, creating a self-perpetuating cy…
Preview only. Read the full abstract at the source